A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer-Reference-Cited by-同舟云学术

A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer

Published:2022-04 Issue:4 Volume:34 Page:261-266
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Lerner A.,Keshwani K.,Okines A.,Sanderson B.,Board R.E.,Flynn M.,Sharkey E.,Konstantis A.,Roylance R.,Hanna D.,King J.,Murphy R.,Rehman F.,Guppy A.E.,Westbury C.,Takeuchi E.,Spurrell E.,Jayaweera H.K.,Raja F.

Funder

Roche

TG Therapeutics

Pfizer

AstraZeneca

Daiichi-Sankyo

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference17 articles.

1. Cancer Research UK. Breast cancer incidence (invasive) statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive. Accessed 11 April 2021.

2. Fulvestrant in combination with CDK4/6 inhibitors for HER2– metastatic breast cancers;Iorfida;Curr Perspect Breast Cancer,2020

3. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer;Di Leo;J Clin Oncol,2010

4. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study;Robertson;J Clin Oncol,2009

5. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial;Robertson;Lancet,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

2. Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review;Frontiers in Endocrinology;2024-03-13

3. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer;Current Oncology;2023-06-24